Table 1 |
|
|
Patient characteristics at baseline |
|
|
Characteristic |
Mean + SD or n(%) |
|
|
|
|
Total number of patients |
117 |
|
Female |
105 (89.7%) |
|
Age at PAH diagnosis*, years |
61.5 ± 11.4 |
|
Disease duration at PAH diagnosis*, years |
11.7 ± 11.3 |
|
Race |
|
|
Caucasian |
101 (86.3%) |
|
Asian |
10 (8.5%) |
|
Aboriginal/Torres Strait Islander |
3 (2.6%) |
|
Hispanic |
1 (0.9%) |
|
Other |
2 (1.7%) |
|
Underlying CTD |
|
|
Limited SSc |
79 (72.5%) |
|
Diffuse SSc |
25 (21.4%) |
|
MCTD |
5 (4.5%) |
|
SLE |
3 (2.8%) |
|
RA |
3 (2.8%) |
|
Undifferentiated CTD |
2 (1.8%) |
|
Anti-centromere antibody positive |
56 (47.9%) |
|
Anti-Scl-70 antibody positive |
9 (7.7%) |
|
Anti-phospholipid antibodies |
27 (23.1%) |
|
WHO functional class |
|
|
Class I |
9 (7.7%) |
|
Class II |
14 (12.0%) |
|
Class III |
88 (75.2%) |
|
Class IV |
6 (5.1%) |
|
Baseline 6MWD, m |
325 ± 127 |
|
Baseline mRAP, mm Hg |
6.9 ± 4.2 |
|
Baseline mPAP, mm Hg |
35.9 ± 12.4 |
|
Baseline PCWP, mmHg |
9.7 ± 3.9 |
|
Baseline CI, L/min/m2 |
2.6 ± 0.8 |
|
Baseline PVR, Wood units |
6.9 ± 6.1 |
|
Pericardial effusion |
14 (12.0%) |
|
Warfarin therapy |
36 (30.8%) |
|
Pulmonary vasodilator therapy |
|
|
Monotherapy |
70 (59.8%) |
|
Sequential monotherapy |
12 (10.3%) |
|
Combination therapy |
34 (29.0%) |
|
|
|
|
* date of PAH diagnosis is the date of right heart catheterisation 6MWD, six minute walk distance; CI, cardiac index; CTD, connective tissue disease; MCTD, mixed connective tissue disease; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; WHO, World Health Organization |
|
|
Ngian et al. Arthritis Research & Therapy 2012 14:R213 doi:10.1186/ar4051 |
|
